secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARDELYX, INC. (ARDX)
CIK:        0001437402
Form:       8-K
Filed at:   2023-02-15T23:59:59+00:00
Accession:  0001628280-23-003565
Event type: debt
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 2.03
LLM model:  deepseek-v4-flash:cloud@v2

Ardelyx amends SLR loan; extends interest-only and draw deadlines conditional on FDA tenapanor decision
--------------------------------------------------------------------------------

- Interest-only period extended to April 1, 2025 if FDA approves tenapanor hyperphosphatemia NDA by Nov 30, 2023 or 2023 revenue milestones met.
- Draw period for additional $22.5M Term B Loan extended to Dec 20, 2023, tied to same FDA approval timeline.
- Interest rate revised to 7.95% + greater of 1% or (0.022% + 1-month CME Term SOFR).
- Amendment provides financial flexibility while awaiting FDA decision on tenapanor.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1437402/000162828023003565/0001628280-23-003565-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1437402/000162828023003565/ardx-20230209.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-003565

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer